Shifting paradigms in cancer clinical trial design

Nature Reviews Clinical Oncology

Volumn 11, Issue 11, 2014, Pages 625-626

  Sargent, Daniel J ^a   Korn, Edward L ^b  

^a MAYO CLINIC   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; DECISION MAKING; DISEASE ASSOCIATION; DISEASE MARKER; EXPERIMENTAL DESIGN; HUMAN; MALIGNANT NEOPLASTIC DISEASE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SELECTION; PREDICTION; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZATION; SHORT SURVEY; SURVIVAL RATE; TREATMENT PLANNING; CLINICAL TRIAL (TOPIC); DISEASE FREE SURVIVAL; FEMALE; MALE; METHODOLOGY; NEOPLASMS; PROCEDURES; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; TRENDS;

CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; NEOPLASMS; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT SELECTION; RESEARCH DESIGN; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84908498383     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2014.167     Document Type: Short Survey

References (10)

1. Sherman, R. E., Li, J., Shapley, S., Robb, M. & Woodcock, J. Expediting drug development-the FDA's new "breakthrough therapy" designation. N. Eng. J. Med. 369, 1877-1880 (2013).
2. Rubinstein, L. V. et al. Design issues of randomized phase II trials and a proposal for phase II screening trials. J. Clin. Oncol. 23, 7199-7206 (2005).
3. Seymour, L. et al. The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the National Cancer Institute Investigational Drug Steering Committee. Clin. Cancer Res. 16, 1764-1769 (2010).
4. Korn, E. L., Freidlin, B., Abrams, J. S. & Halabi, S. Design issues in randomized phase II/III trials. J. Clin. Oncol. 30, 667-671 (2012).
5. Sargent, D. J., Conley, B. A., Allegra, C. & Collette, L. Clinical trial designs for predictive marker validation in cancer treatment trials. J. Clin. Oncol. 23, 2020-2027 (2005).
6. Kim, E. S. et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 1, 44-53 (2011).
7. Barker, A. D. et al. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin. Pharmacol. Ther. 86, 97-100 (2009).
8. Abrams, J. et al. National Cancer Institute's precision medicine initiatives for the new National Clinical Trials Network. Am. Soc. Clin. Oncol. Educ. Book 2014, 71-76 (2014).
9. Burzykowski, T., Molenberghs, G. & Buyse, M. (eds) The Evaluation of Surrogate Endpoints (Springer, 2005).
10. Ellis, L. M. et al. American Society of Clinical Oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes. J. Clin. Oncol. 32, 1277-1280 (2014).